Breast Cancer

3:14
How to manage elderly patients on immunotherapy
Matti Aapro
2:30
Highlighting a subset of TNBC for targeted therapy
Adrian Harris
2:47
Current treatment landscape of triple negative breast cancer
Adrian Harris
1:26
Breast cancer driver mutations in Saudi Arabia
Ahmed Saadeddin
2:15
Outlook for HR+/HER2- advanced breast cancer treatment
Ahmed Saadeddin
1:21
The challenges of treatment sequencing in HR+ breast cancer patients
Ahmed Saadeddin
0:51
Challenges in the treatment of mTNBC
Peter Schmid
1:01
The future therapeutic landscape of immunotherapy for mTNBC
Peter Schmid
2:52
IMpassion130 study: improvement in OS and PFS for IIT and PD-L1+ populations with mTNBC
Peter Schmid
3:38
SOLO-1: practice changing results for advanced ovarian cancer
Susana Banerjee
4:51
SOLAR-1: alpelisib plus fulvestrant for advanced breast cancer
Fabrice André
5:04
PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer
Massimo Cristofanilli
7:08
IMpassion130: results of atezolizumab plus nab-paclitaxel for frontline TNBC
Peter Schmid
1:38
The importance of HCPs feeling comfortable and confident with biosimilars
Justin Stebbing
1:27
Education is key to improve confidence in biosimilars
Justin Stebbing
2:33
Positive results for trastuzumab biosimilar CT-P6 in HER2+ early breast cancer
Justin Stebbing
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals